DDInter923 DDInter298
Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory cytokine involved in chronic inflammatory diseases. Its hyperactivity and enhanced signalling pathways can be observed in inflammatory diseases where it activates further pro-inflammatory cascades. By binding to both the soluble subunit and the membrane-bound precursor of TNF-α, infliximab disrupts the interaction of TNF-α with its receptors and may also cause lysis of cells that produce TNF-α. Infliximab was first approved by the FDA in 1998 under the market name Remicade as an intravenous injection. It is indicated for the treatment
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Cisplatin
Cisplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Capecitabine
Capecitabine {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Cisplatin
Cisplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Carboplatin
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Mitomycin
Mitomycin {u} (Compound) upregulates {v} (Gene) SLC31A2
SLC31A2 {u} (Gene) is bound by {v} (Compound) Carboplatin
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) treats {v} (Disease) uterine cancer
uterine cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) palliates {v} (Disease) breast cancer
breast cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) causes {v} (Side Effect) Venous thrombosis
Venous thrombosis {u} (Side Effect) is caused by {v} (Compound) Carboplatin
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Cisplatin
Cisplatin {u} (Compound) is included by {v} (Pharmacologic Class) Platinum-containing Compounds
Platinum-containing Compounds {u} (Pharmacologic Class) includes {v} (Compound) Carboplatin
Infliximab {u} may lead to a major life threatening interaction when taken with {v} Betamethasone
Betamethasone {u} (Compound) palliates {v} (Disease) brain cancer
brain cancer {u} (Disease) is treated by {v} (Compound) Carboplatin
Infliximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Dapsone
Dapsone {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is bound by {v} (Compound) Carboplatin
Infliximab may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Carboplatin (Compound)
Infliximab may lead to a major life threatening interaction when taken with Capecitabine and Capecitabine (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)
Infliximab may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Carboplatin (Compound)
Infliximab may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin (Compound) upregulates SLC31A2 (Gene) and SLC31A2 (Gene) is bound by Carboplatin (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) treats uterine cancer (Disease) and uterine cancer (Disease) is treated by Carboplatin (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Carboplatin (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) causes Venous thrombosis (Side Effect) and Venous thrombosis (Side Effect) is caused by Carboplatin (Compound)
Infliximab may lead to a major life threatening interaction when taken with Cisplatin and Cisplatin (Compound) is included by Platinum-containing Compounds (Pharmacologic Class) and Platinum-containing Compounds (Pharmacologic Class) includes Carboplatin (Compound)
Infliximab may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone (Compound) palliates brain cancer (Disease) and brain cancer (Disease) is treated by Carboplatin (Compound)
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Dapsone and Dapsone (Compound) binds MPO (Gene) and MPO (Gene) is bound by Carboplatin (Compound)